Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth
- 31 March 2012
- journal article
- research article
- Published by Elsevier BV in Bone
- Vol. 50 (3), 695-703
- https://doi.org/10.1016/j.bone.2011.11.022
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Blockade of transforming growth factor‐beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell lineThe Prostate, 2011
- Quantification of Mineralized Bone Response to Prostate Cancer by Noninvasive In Vivo μCT and Non-Destructive Ex Vivo μCT and DXA in a Mouse ModelPLOS ONE, 2010
- TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formationNature Medicine, 2009
- Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on BonePLOS ONE, 2009
- Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-β Receptor Type I Inhibitor as Antitumor AgentJournal of Medicinal Chemistry, 2008
- In vivo imaging of prostate cancer involving bone in a mouse modelThe Prostate, 2006
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- TGF-β signaling: positive and negative effects on tumorigenesisCurrent Opinion in Genetics & Development, 2002
- Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalaciaCancer, 1983